Sterling Capital Management’s Acadia Pharmaceuticals ACAD Stock Holding History

Sterling Capital Management’s Portfolio ACAD Stock Details ACAD Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q2	$13.6K	Sell	537 -362	-40%	-$7.96K	﹤0.01%	2068
2026 Q1	$20K	Buy	899 +9	+1%	+$215	﹤0.01%	2028
2025 Q4	$23.8K	Buy	890 +504	+131%	+$12K	﹤0.01%	2134
2025 Q3	$8.24K	Buy	386 +1	+0.3%	+$24	﹤0.01%	2595
2025 Q2	$8.3K	Buy	385 +173	+82%	+$3.22K	﹤0.01%	2245
2025 Q1	$3.52K	Buy	212 +6	+3%	+$109	﹤0.01%	2329
2024 Q4	$3.78K	Sell	206 -42	-17%	-$678	﹤0.01%	2577
2024 Q3	$3.81K	Buy	+248	New	+$4.14K	﹤0.01%	1868

Other funds holding ACAD

BBA

Baker Bros. Advisors New York $20B AUM 154.41% 1-Year Est. Return

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return

Vanguard Portfolio Management Malvern, Pennsylvania $2.22T AUM

RTW Investments New York $11.7B AUM 174.13% 1-Year Est. Return

Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM

Dimensional Fund Advisors Austin, Texas $552B AUM 44.19% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return

PAI

Palo Alto Investors Palo Alto, California $724M AUM 96.91% 1-Year Est. Return

Goldman Sachs New York $1.15T AUM 47.82% 1-Year Est. Return

Sterling Capital Management's ACAD Position: Q2 2026 in Review

Sterling Capital Management reduced its Acadia Pharmaceuticals (ACAD) stake by 40% in Q2 2026, selling an estimated $7.96K and leaving 537 shares worth $13.6K. The position accounts for ﹤0.01% of the portfolio, ranked #2068.

Sterling Capital Management first reported a position in ACAD in Q3 2024 and has held it in 8 quarters since. The position peaked at $23.8K in Q4 2025. 354 funds tracked by Wall St. Rank hold ACAD as of Q2 2026.

Sterling Capital Management held 537 shares of Acadia Pharmaceuticals worth $13.6K as of Q2 2026.
Sterling Capital Management sold 362 Acadia Pharmaceuticals shares in Q2 2026, an estimated $7.96K.
Acadia Pharmaceuticals made up ﹤0.01% of Sterling Capital Management's portfolio in Q2 2026, its #2068 holding.
Sterling Capital Management first reported a position in Acadia Pharmaceuticals in Q3 2024 and has held it in 8 quarters since.
Sterling Capital Management's Acadia Pharmaceuticals position peaked at $23.8K in Q4 2025.
354 funds tracked by Wall St. Rank held Acadia Pharmaceuticals as of Q2 2026.

Based on Sterling Capital Management's 13F filing for Q2 2026, filed 28 Jul 2026.